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ABSTRACT 
Neurodegenerative diseases are a heterogeneous group of disorders that are 
characterized by the progressive degeneration of structure and function of the nervous 
system. They include diseases such as Alzheimer’s disease (AD), multiple sclerosis 
(MS) and others. The main aims of this thesis were to study functional and/or 
structural brain changes in AD and MS using novel magnetic resonance imaging 
(MRI) techniques.  
 
The concentration of β-amyloid1-42 (Aβ42), total tau (T-tau) and tau phosphorylated at 
position threonine 181 (P-tau181p) in cerebrospinal fluid (CSF) may reflect brain 
pathophysiological processes in AD. We found a positive correlation between 
functional connectivity within the default mode network (DMN) and the ratio of 
Aβ42/P-tau181p in sporadic AD (Paper I). Furthermore, there were correlations 
between AD CSF biomarkers and changes of gray matter volume, fractional 
anisotropy (FA) and mean diffusivity (MD). The majority of brain regions with 
statistically significant correlation with biomarkers of AD overlapped with the DMN 
(Paper II). These findings implicate that the brain functional connectivity and 
structure are affected by pathological changes at an early stage in AD. We also found 
a significantly increased MD in pre-symptomatic mutation carriers (pre-MCs) of AD 
compared with non-carriers (NCs), and increased MD associated with AD CSF 
biomarkers (Paper III). Similar results were observed both in sporadic and familial 
AD, which suggests that MD may reflect pathology of early stage AD. Although the 
exact causes of these changes are difficult to identify, the increased MD may be 
explained by myelin loss.  In MS, myelin loss is one of the characteristic events of 
the pathological process. By combining susceptibility-weighted MRI with analysis of 
the 𝑇!∗ decay curves, we were able to characterize and quantify myelin loss (Paper 
IV).  
 
In conclusion, pathological changes in AD and MS could be detected by novel MRI 
techniques. This suggests that these techniques may also be helpful in further 
understanding pathology in other neurodegenerative diseases. As non-invasive tools, 
these novel MRI techniques are possible to screen individuals susceptible to and/or 
manifesting early neurodegeneration.  
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1 INTRODUCTION 
1.1 Neurodegenerative diseases 
Neurodegenerative diseases are traditionally defined as disorders with progressive 
loss of neurons in distinct anatomical distribution, and accordingly different clinical 
phenotypes (Kovacs and Budka, 2010). This includes diseases such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral 
sclerosis and others. These diseases are relatively common, especially AD, PD and 
MS.  
 
Neurodegenerative diseases occur when neurons in the brain and spinal cord begin to 
deteriorate. Changes in these cells cause them to function abnormally and eventually 
result in the death of the cells. These diseases generally begin slowly but inexorably 
cause progressive neuronal degeneration and result in disability or death. An 
individual may first experience relatively mild problems. But as large numbers of 
neurons die, symptoms progressively worsen. In some cases, patients lose the general 
function in their life, the ability to think clearly and/or walk independently. 
Ultimately, many of these diseases are fatal.  
 
Traditionally, different diagnoses of neurodegenerative diseases, such as AD and MS, 
have been thought to present with different symptoms and arise through different 
disease processes. However, while many different forms of neurodegenerative 
diseases are recognized, the lines that separate one from another are often unclear. 
For instance, symptoms such as motor impairment and memory loss may occur in 
many different types of neurodegenerative disease. It is therefore difficult to reach an 
accurate diagnosis before the patient reaches a more advanced stage of the disease.  
 
Neuropathological evaluation, which is often considered the gold standard of 
diagnosis, can also show marked overlap between the syndromes of age-related 
cognitive and motor impairment. Upon histological examination, the brains of 
individuals with different neurodegenerative disorders show characteristic cellular 
and tissue abnormalities. However, it has been shown that the brains of individuals 
with one form of neurodegeneration could also have the pathological markers of 
another (Schneider et al., 2007).  Co-pathology of amyloid β (Aβ) and tau is present 
in several neurodegenerative diseases, including AD, PD, and some cases of multiple 
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system atrophy (Kovacs and Budka, 2010). Moreover, the presence of soluble 
oligomers, common to most amyloids, in MS brains has been demonstrated (David 
and Tayebi, 2014).  
 
Neurodegenerative diseases share several common features with respect to clinical 
course, pathology, and molecular mechanisms. However, the mechanisms responsible 
for their pathologies are not completely understood, and there are currently no 
effective preventive therapies. Some studies have demonstrated that these disorders 
are characterized by a pre-symptomatic phase, likely lasting years, during which 
neuronal degeneration is occurring but before clinical symptoms appear (DeKosky 
and Marek, 2003). Thus, there is a need for the development of non-invasive 
detection tools to identify individuals at early stage, or even during the preclinical 
period. Moreover, early detection of neurodegenerative diseases would be beneficial 
in understanding the pathologies mechanism and progression from the very 
beginning, and would enable preventive and more effective treatment of the patients.  
 
1.2 Alzheimer’s disease 
Originally reported by the German psychiatrist Alois Alzheimer in 1907, AD has 
become the most common neurodegenerative disease worldwide. In 2010, 35.6 
million persons suffered from dementia worldwide, most from AD. It has been shown 
that the prevalence and incidence of dementia increases exponentially between the 
ages of 65 and 85, doubling in every five-year age group. Based on these numbers, it 
has been projected that the number of persons with dementia will reach 65.7 million 
in 2030, and 115.4 million in 2050 (Alzheimer’s Disease International, 2009).  
 
AD is clinically characterized by progressive cognitive impairment decline leading to 
complete dependence on care within some years after clinical diagnosis. Disease 
onset is typically characterized by loss of memory for recent events, but later 
develops into a more severe disorder including: visuospatial problems, dysphagia, 
anemia, orientation difficulties, anxiousness, irritability, and severe cognitive and 
intellectual disturbances. Eventually, patients no longer function normally. Mild 
cognitive impairment (MCI) is recognized as the prodromal stage of AD, representing 
a transitional period between normal aging and AD (Petersen et al., 1997; Albert et 
al., 2011). Subjects with MCI developed dementia, usually AD, at a rate of 10% to 
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15% per year, which is much higher than in age-matched controls (1% to 2% per 
year) (Petersen et al., 1997). More than half of MCI patients progress to dementia 
within three to five years (Petersen et al., 2001). There is evidence indicating that 
subjective cognitive impairment (SCI), also referred to as subjective memory 
complaints or subjective cognitive decline, is a stage prior to MCI in the eventual 
development of AD dementia (Reisberg and Gauthier, 2008; Jessen et al., 2014). A 
probable duration of 15 years for the SCI stage has been supported by a longitudinal 
study (Glodzik-Sobanska et al., 2007).  
 
Two abnormal protein aggregates characterize AD pathologically. These 
proteinopathies are the basis of the well-known amyloid plaques (APs) and 
neurofibrillary tangles (NFTs) (Jack, 2012). APs form in the extracellular space, 
while NFTs are intracellular aggregates, containing Aβ and hyperphosphorylated tau, 
respectively (Blennow et al., 2006). Under physiological conditions, Aβ peptides of 
39-43 amino acids are the peptide products of the larger amyloid precursor protein, 
with Aβ40 being by far the most abundant (Masters et al., 1985; Iwatsubo et al., 
1994). Aβ42 aggregates more readily than other species into soluble oligomers, and 
insoluble fibrils characterized by a β-pleated sheet conformation, eventually forming 
the AD-typical plaques (Iwatsubo et al., 1994). In amyloid cascade hypothesis of AD, 
an imbalance between the production and clearance of Aβ in the brain is the initiating 
event, ultimately leading to dementia (Hardy and Selkoe, 2002). Tau is a 
phosphoprotein and component of the cytoskeletal microtubule system. In AD, tau 
becomes hyperphosphorylated, disassociates from microtubules, assumes a paired 
helical filament configuration, and forms insoluble NFTs inside neurons (Jack, 2012). 
 
Progression of APs and NFTs pathology throughout the brain (a process that has been 
called ‘spreading’) generally proceeds in a particular manner. APs develop in poorly 
myelinated areas of the basal neocortex, then spread into adjoining areas and the 
hippocampus, and eventually infiltrate all cortical areas, including densely myelinated 
primary fields of the neocortex (Braak and Braak, 1997). The NFTs pathologic 
process of AD begins in the transentorhinal area and progresses to the hippocampus, 
then to paralimbic and adjacent medial-basal temporal cortex, to neo-cortical 
association areas, and lastly to primary sensorimotor and visual areas (Braak and 
Braak, 1991). Such brain changes occur decades before the onset of dementia, leading 
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to progressive loss of functions, metabolic alterations and structural changes in the 
brain (Morris and Price, 2001). 
 
Several susceptibility genes have been identified in connection with AD. The most 
consistently associated is the ε4 allele of the apolipoprotein E gene (APOE) (Bertram 
and Tanzi, 2012). APOE exists in three isoforms ε2, ε3, and ε4. APOE ε4 allele 
implies a three-fold increase in risk of AD in heterozygotes and 15 times in 
homozygotes (Farrer et al., 1997), whereas the APOE ε2 allele decreases risk (Albert 
et al., 2011). APOE ε4 may affect AD pathogenesis by promoting deposition of the 
Aβ and formation of plaque (Holtzman et al., 2000).  
 
Genetic factors are important in all forms of AD but especially in familial AD (FAD). 
They are characterized by early-onset, before 60 years of age, a strong familial 
aggregation, which accounts for only about 1% to 6% of all AD cases (Alonso 
Vilatela et al., 2012). Similar to sporadic AD, most FAD cases present with an 
insidious onset of episodic memory difficulties followed by other cognitive 
impairments (Bateman et al., 2011). FAD exhibits the same pathological hallmarks as 
sporadic AD, including APs and NFTs (Shepherd et al., 2009). Currently, pathogenic 
mutations in three genes have been identified: amyloid precursor protein (APP), 
presenilin 1 (PSEN1), and PSEN2 (Bertram et al., 2010), which are all involved in the 
Aβ pathway (Wu et al., 2012; Wanngren et al., 2014). PSEN1 mutations are 
responsible for nearly 75-80% of genotype-positive families in a mutation, APP and 
PSEN2 mutations are responsible for 15-20% and less than 5%, respectively (Wu et 
al., 2012). PSEN1 mutation carriers (MCs) have an average age of symptom onset 
(AAO) in the early 40s, ranging from 24 to 65 years. While APP MCs have a later 
AAO, typically in the 50s and ranging from 45 to 60 years; and PSEN2 mutations 
have a wide range of onset with some relatively late-onset cases (Bateman et al., 
2011). Due to nearly 100% penetrance in FAD MCs, serial neuroimaging or CSF 
examination in the early stage of the MCs provides an opportunity to identify early 
biomarkers of FAD that can be used to track disease progression from the pre-
symptomatic stage through to dementia (Wu et al., 2012).  
 
The brain is in direct contact with the cerebrospinal fluid (CSF). Biochemical changes 
that reflect pathophysiologic processes in the brain are reflected in the CSF (Tapiola 
et al., 2009; Engelborghs and Bastard, 2012). Concentrations of Aβ42, total tau (T-
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tau) and tau phosphorylated at position threonine 181 (P-tau181p) in CSF may be 
sensitive biomarkers of incipient APs and NFTs formation in AD. Both Aβ42 and tau 
proteins of CSF can be reliably measured (Vandermeeren et al., 1993; Vanmechelen 
et al., 2000). It has been reported that CSF Aβ42 concentrations are decreased, while 
T-tau and P-tau181p concentrations are increased in AD patients, even in MCI and SCI 
patients (Blennow et al., 2006; Hansson et al., 2006; Visser et al., 2009). 
Furthermore, decreased Aβ42 and increased P-tau181p and T-tau in CSF have been 
found in APP and PSEN1 MCs (Ringman et al., 2008; Wu et al., 2012). CSF Aβ42 is 
reduced in AD which may be associated with the deposition of the peptide in plaques 
with lower concentrations diffusing to the CSF. CSF T-tau and P-tau181p are increased 
probably as a result of neuronal and axonal degeneration (Blennow et al., 2006). The 
correlation of these CSF biomarkers and AD pathological hallmarks has also been 
confirmed in a neuropathological study. Seppälä et al (Seppälä et al., 2012) 
demonstrated that APs and hyperphosphorylated tau in cortical brain biopsies were 
reflected by low CSF Aβ42 and high CSF T-tau and P-tau181P levels, respectively. The 
diagnostic accuracy of the CSF biomarkers has been assessed in some studies 
(Ferreira et al., 2014a). The diagnostic sensitivities for CSF Aβ42 and T-tau in AD 
against cognitively normal elderly people were 80% and 82%, and the specificities 
were 82% and 90% respectively. The addition of CSF P-tau181P increases the ability to 
differentiate AD from other dementias (OD), reaching specificity around 80%. 
Moreover, concentrations of CSF Aβ42, T-tau and P-tau181P also showed strong 
association with future development of AD in patients with MCI (Hansson et al., 
2006). The combination of Aβ42 and P-tau181p was the most predictive assay for AD 
among MCI patients (Herukka et al., 2005; Ferreira et al., 2014b). 
 
1.3 Multiple sclerosis 
More than 100 years have passed since Jean-Martin Charcot first described MS as 
‘sclerose en plaques’ (Makris et al., 2013). MS is one of the most common 
neurological disorders and causes of disability in young adults. Globally, the median 
estimated prevalence of MS is 30 per 100 000 (with a range of 5–80), depending on 
the region, and is highest in Europe (80 per 100 000), Eastern Mediterranean (14.9) 
and the Americas (8.3). An estimated 2.6 million worldwide were diagnosed with MS, 
of which approximately 630 000 were in Europe and 520 000 in the Americas, 
(World Health Organization, 2008).  
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The main feature of MS is a variable neurological dysfunction showing characteristic 
relapses and remissions without any specific pattern. Four main subtypes are defined 
according to the natural history of the disease: relapsing remitting MS (RRMS), 
which is the most common, including almost 85% of the patients affected, primary 
progressive MS, progressive relapsing MS, and secondary progressive MS (Figure 1) 
(Noseworthy et al., 2000). Symptoms may involve the entire ascending or descending 
axons and can sometimes predominantly affect the spinal cord and optic nerves 
(Compston and Coles, 2002). The most common clinical signs include sensory 
disturbance, unilateral optic neuritis, limb weakness, clumsiness and cognitive 
dysfunction (Noseworthy et al., 2000). The rating of the neurologic impairment in 
MS is mostly evaluated using the expanded disability status scale (EDSS) (Kurtzke, 
1983), which is also a useful tool for predicting future disability (Chruzander et al., 
2013).  
 
MS is generally believed to be an immune-mediated disorder of the central nervous 
system characterized by extensive myelin loss (Haines et al., 2011). Focal lesions are 
the diagnostic hallmark of MS pathology, which consist of demyelination, 
inflammation, scar formation and variable axonal destruction (Pittock and 
Lucchinetti, 2007).  The cores of the lesions are filled with a central vein that is 
surrounded by inflammatory components and demyelination, which occur in the 
 
Figure 1. Progression of MS subtypes. 
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white matter (WM) and gray matter (GM) in the brain and spinal cord (Lassmann et 
al., 2012). MS lesions can be characterized as active and inactive (Lassmann et al., 
1998). Active lesions are heavily infiltrated by macrophages containing myelin debris 
that are often closely associated with the disintegrating myelin sheath, while the 
chronic inactive MS lesion is a hypocellular plaque with no evidence of active myelin 
breakdown. Fibrillary gliosis is prominent and axonal density is often markedly 
reduced in chronic inactive plaque (Pittock and Lucchinetti, 2007).  
 
Several mechanisms have been proposed to explain the pathogenesis of progressive 
MS (Lassmann et al., 2012). One of these mechanisms postulates that brain damage is 
driven by inflammatory processes. Another potential mechanism suggests that MS 
starts as an inflammatory disease and after several years of chronic inflammation, 
neurodegeneration, which is independent of inflammatory response, results in disease 
progression. Finally, others have suggested that MS might be primarily a 
neurodegenerative disease, the progression of which is modified or amplified by 
inflammation in the early disease stage. Relapses are considered as recurrent episodes 
of inflammation and demyelination, often accompanied by axonal injury. Remission 
of symptoms after an attack may relate to resolution of inflammation and/or 
remyelination (Pittock and Lucchinetti, 2007). Unfortunately, neither clinical nor 
pathologic features clearly predict clinical course or outcome. 
 
It is still not known what causes MS, but it is believed that this disease occurs as a 
result of both environmental and genetic factors. Genetic studies have identified many 
MS risk-gene regions (Katsavos and Anagnostouli, 2013). However, the distribution 
of MS cannot be explained on the basis of population genetics alone (Compston and 
Coles, 2002). In other words, it is likely that the risk genes contribute or indirectly 
influence interactions with the currently known environmental risk factors, including 
decreased sun exposure, vitamin D deficiency, viral infections (particularly Epstein-
Barr virus), and smoking (Burrell et al., 2011).  
 
Information on the oligoclonal IgG bands in CSF is useful for MS diagnosis. The 
diagnostic sensitivity is high (>90%), while the specificity among inflammatory 
disorders of the central nervous system is only around 35% (Katsavos and 
Anagnostouli, 2013), and could not differentiate subtypes of MS (Stangel et al., 
2013). Some other biomarkers for MS include osteopontin, TNF-alpha, and various 
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cytokines, and have been reported with different sensitivity and specificity (Katsavos 
and Anagnostouli, 2013). So far, none of the existing biomarkers can fully reflect the 
immensity of diverse MS pathogenic mechanisms creating a unique result. 
 
1.4 Magnetic resonance imaging 
In the past two decades, magnetic resonance imaging (MRI) has been playing an 
increasingly important role in the study and clinical diagnosis of neurodegenerative 
diseases.  
 
MRI is a non-invasive method that uses the resonance of protons to create a signal, 
which is then processed to generate images. Hydrogen atoms are the most common 
protons to create the signal and are excited by a radiofrequency pulse with a specific 
frequency, the same frequency as the protons. When the radiofrequency is switched 
off, the excited protons emit energy in a radio frequency signal as they return to their 
original state; this process is called relaxation. The relaxation starts both 
longitudinally and transversely. Longitudinal relaxation, known as spin-lattice 
relaxation, refers to the process in which the excited protons return the energy to the 
surroundings. While transverse relaxation, also known as spin-spin relaxation, is 
observed due to the interactions of excited protons dephasing from each other. The 
relaxation rates are characterized by two relaxation times, 𝑇! and 𝑇!, respectively. In 
real systems, however, the transverse relaxation decays much faster than would be 
predicted by natural atomic mechanisms; this rate is called as 𝑇!∗ , which is a 
combination of “true” 𝑇!  relaxation and relaxation caused by magnetic field 
inhomogeneity (Chavhan et al., 2009). Variations in proton relaxation times are the 
primary cause of contrast in MRI; however proton density is also an important factor. 
Besides these, the diffusion coefficient is widely used to generate contrast based on 
the physical properties of water molecules, which represents the thermal (or 
Brownian) motion of water molecules (Mori and Zhang, 2006). The images generated 
with different contrasts are called 𝑇!-weighted imaging (𝑇!-w), 𝑇!-weighted imaging 
(𝑇!-w), 𝑇!∗-weighted imaging (𝑇!∗-w), proton density and diffusion-weighted imaging 
(DWI) respectively. 
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Novel MRI techniques from structure to function are widely used to investigate the 
brain abnormalities associating with vulnerability to develop neurodegenerative 
diseases and their progression. 
 
1.4.1 MRI techniques 
1.4.1.1 Resting-state functional MRI 
Resting-state functional MRI (rs-fMRI) is a type of specialized MRI scan with a fast 𝑇!∗ sensitive sequence that uses blood-oxygen-level-dependent contrast to measure the 
hemodynamic response (change in blood flow) related to spontaneous activity in the 
brain at resting state. The synchrony between low frequency fluctuations in signal 
intensity of rs-fMRI data has been used as a measure of functional connectivity in 
spatially separated brain regions (Biswal et al., 1997). Although the precise 
physiologic mechanism measured with functional connectivity is not fully 
understood, there is much evidence in support of the notion that the coordinated 
activity changes in the brain are related to the establishment or maintenance of 
synaptic connections between neurons (Leopold and Maier, 2012). rs-fMRI has been 
successfully used to map connectivity between distant brain regions that are 
functionally related (Greicius et al., 2004). 
 
1.4.1.2 Voxel-based morphometry 
Voxel-based morphometry (VBM) is a neuroimaging analysis technique that 
compares the local intensity of brain tissue at every voxel to assess structural 
characteristics such as volume or density in neuroanatomy. VBM consists of spatially 
normalizing high-resolution 𝑇!-w from every subject in the study to the same space 
(standard or study template), which gets rid of most of the large differences in brain 
anatomy among people. Then, the spatially normalized image is segmented into the 
GM, WM and CSF, and smoothed so that each voxel represents the average of itself 
and its neighbors. Finally, the image volume is compared across brains at every 
voxel. Compared to traditional manually morphometric methods, such as the manual 
delineation of specific regions of interest, VBM approach is not biased to one 
particular structure and gives an comprehensive assessment of anatomical differences 
throughout the brain (Ashburner and Friston, 2000). 
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1.4.1.3 Diffusion tensor imaging 
Compared to morphometric methods that measure the macrostructural damage of 
disease (e.g. VBM), diffusion tensor imaging (DTI) measurements evaluate the 
microstructural damage of disease. DTI is a quantitative MRI technique that measures 
the movement of water within the tissue microstructure (Chua et al., 2008). The two 
most common measurements are fractional anisotropy (FA) and mean diffusivity 
(MD). FA is a measure of anisotropic water diffusion, and reflects the degree of 
directionality of cellular structures within the fiber tracts and therefore their structural 
integrity. In a purely isotropic media, FA would be 0, and with increasing anisotropy 
the value tends towards 1. MD provides an index of average diffusional motions of 
water molecules. The loss of macromolecular tissue content results in an increase in 
free water diffusion and consequentially increased MD. The changes in FA and MD 
can, therefore, be related back to abnormalities within the cellular microstructure to 
provide information about their structural integrity.  
 
1.4.1.4 Separation of 𝑇!∗ relaxation components 
Multi-gradient-echo imaging (mGRE) for mapping the 𝑇!∗ relaxation decay curve has 
been proposed as a new way to obtain cellular compartment-specific information in 
WM (Du et al., 2007; Hwang et al., 2010; van Gelderen et al., 2012; Sati et al., 2013). 
Since the myelin sheath acts as a water diffusion-restricting barrier due to its 
multilayer structure, it is indeed generally accepted that three major distinct water 
pools can be distinguished in WM (Lancaster et al., 2003; Laule et al., 2004;  
Andrews et al., 2005; MacKay et al., 2006): water between the myelin layers (or 
myelin water), interstitial water (or extracellular water) and intra-axonal water. Under 
the assumption of a slow-exchange process between these pools, one would observe 
multi-exponential 𝑇!∗ decay as a function of echo time (TE) for myelin containing 
tissue (van Gelderen et al., 2012). Therefore, information about the relative sizes of 
myelin water and axonal water pools could be gained from fitting a three-component 
model to the 𝑇!∗  relaxation curve. This could provide new insights into myelin 
breakdown, axonal injury and degenerative processes. 
 
1.4.2 MRI in AD 
Due to the uncertainties associated with the clinical diagnosis, a variety of novel 
imaging modalities including structural, functional, and molecular neuroimaging 
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techniques have been adopted for identifying specific diagnostic patterns in 
individuals who may be at risk of AD.  
 
A progressive accumulation of amyloid and NFTs in the brain tissue eventually result 
in neuronal death and diffuse brain atrophy (Figure 2) (Anand et al., 2012), which 
can be measured by MRI. VBM has been extensively used to measure morphological 
changes in AD studies during the past two decades (Li and Wahlund, 2011). The 
hippocampus and the entorhinal cortex have been identified as suffering from the 
most severe atrophy in AD (Li and Wahlund, 2011). Atrophy in the medial temporal 
lobe can predict the development of AD and the rate of progression from MCI to AD 
(Korf et al., 2004; Devanand et al., 2007). Furthermore, significant GM atrophy in the 
temporal lobe, precuneus and cingulate gyrus were observed in symptomatic MCs, 
compared with non-carriers (NCs) (Cash et al., 2013). Longitudinal studies have 
demonstrated bilateral hippocampal atrophy in MCs before the appearance of 
symptoms (Fox et al., 1996). Hippocampal volumes of MCs were smaller than those 
of age- and sex-matched control subjects at each stage, but the differences were not 
statistically significant until the MCI stage (Ridha et al., 2006).  
 
In addition to brain atrophy, DTI measurements indicating cerebral damage are 
commonly found in patients with AD and MCI. Altered MD and FA have been 
reported in many different regions. During neurodegeneration, cell loss leads to 
increased diffusion of water molecules that can be quantified by elevated MD. 
Likewise, processes that lead to disturbances of WM structural integrity can be 
 
Figure 2. Brain atrophy in AD.  
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expressed by decreased FA, indicating a disruption of cerebral integrity in the brain 
(Fellgiebel et al., 2004). The most commonly reported regions of DTI alterations are 
the temporal lobes, splenium of corpus callosum and the posterior cingulate area 
(Stebbins and Murphy, 2009; Sexton et al., 2011). DTI measurements in the 
hippocampus are also reliable and precise (Müller et al., 2006) and it has been shown 
that the MD increases in the hippocampus with increasing AD disease severity 
(Cherubini et al., 2010). The alteration pattern in individuals with MCI is similar to 
that seen in patients with AD, but is not as extensive. Decreased FA of the fornix in 
pre-MCs and early symptomatic MCs were reported by Ringman et al (Ringman et 
al., 2007).  Moreover, Ryan et al (Ryan et al., 2013) found widespread decreased FA 
and increased MD in symptomatic MCs, but no significant differences in FA and MD 
were seen for pre-MCs compared with control subjects. 
 
As a biomarker of synaptic dysfunction, rs-fMRI has been widely used in AD studies 
during the past years and may demonstrate abnormality very early in AD (Sperling et 
al., 2011). The rs-fMRI studies for AD mainly focused on a specific set of brain 
regions within the default mode network (DMN) (Raichle et al., 2001). The principal 
regions involved in the DMN are the medial prefrontal cortex, anterior cingulate 
cortex, posterior cingulate cortex/precuneus and medial temporal regions (i.e., 
hippocampal and parahippocampal gyri). This network is active during rest and 
deactivated when individuals are engaged in a broad range of cognitive tasks and it is 
believed to support a default mode activity of the human brain (Buckner et al., 2008). 
The link between DMN and episodic memory is well established. It is known that 
retrieval of episodic memories, whether internally or externally cued, relies on DMN 
(Huijbers et al., 2011). Activation and deactivation patterns within the DMN have 
been found to predict episodic memory performance (Daselaar et al., 2009). Altered 
connectivity within the DMN in AD and MCI has also been reported in many studies 
(Greicius et al., 2004; Wang et al., 2007; Bai et al., 2008; Jones et al., 2011; Petrella 
et al., 2011). The most frequent and consistent finding in both AD and MCI is 
decreased resting state connectivity in the DMN, particularly in the posterior 
cingulate cortex/precuneus and hippocampus, and disruption of DMN connectivity to 
other brain regions (Krajcovicova et al., 2014). Moreover, the decreased functional 
connectivity in the DMN is associated with AD progression (Zhang et al., 2010; 
Petrella et al., 2011). 
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1.4.3 MRI in MS 
MRI was formally integrated into the MS diagnostic criteria in 2000 (McDonald et 
al., 2001), and suggested for monitoring disease evolution and treatment efficacy. On 
MRI, MS plaques are commonly seen as multiple focal lesions with intermediate to 
low signal on 𝑇!-w and high signal on 𝑇!-w / fluid-attenuated inversion recovery 
imaging (FLAIR) (Figure 3). Typical MS lesions are ovoid-shaped with long-axis 
oriented perpendicular to the ventricular surface. Characteristic locations include 
periventricular white matter, corpus callosum, juxtacortical area, and brainstem 
(Barkhof et al., 1997). Inflammation in acute demyelinating MS lesions causes 
increased blood-brain barrier permeability. This leads to contrast enhancement on 
post-gadolinium 𝑇! -weighted imaging (post-gad 𝑇! -w), which is conventionally 
included in MRI acquisition protocols for MS.  
 
Although useful in the diagnosis and management of MS, conventional imaging has 
several limitations. Lesions are nonspecific, and can reflect areas of inflammation, 
demyelination, ischemia, edema, cell loss, or gliosis. Meanwhile, numerous studies 
have attempted to more specifically assess the demyelination process occurring in MS 
by measuring indirectly the local myelin content using various MR techniques, such 
as DTI, magnetization transfer imaging, and 𝑇!-based myelin water imaging (Laule et 
al., 2007). The separation of 𝑇! relaxation components has been used to measure the 
amount of water trapped between the myelin layers, which is generally considered to 
reflect brain myelin content. This is based on the fact that the diffusion-restricting 
properties of myelin lead to distinct 𝑇! values for water between the myelin layers (or 
myelin water), intra-axonal water, and interstitial water (or extracellular water), with 
 
Figure 3. MS lesions on MRI. 
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the myelin water pool having the shortest 𝑇! (MacKay et al., 1994; Lancaster et al., 
2003; Laule et al., 2004; Andrews et al., 2005; MacKay et al., 2006). Decreases in the 
amount of myelin water in MS lesions have been reported by a number of studies 
(MacKay et al., 1994; Vavasour et al., 1998; Laule et al., 2004). Furthermore, 
absence of myelin water signal was also found in chronic demyelinated MS lesions 
(Moore et al., 2000). Although promising, this myelin water measurement method 
generally suffers from long acquisition time, is limited to low field strength MRI (due 
to associated tissue heating), and has limited specificity to myelin water. One very 
recent and particularly promising technique to measure myelin associated water is the 
use of 𝑇!∗ contrast (van Gelderen et al., 2012; Sati et al., 2013). Similar to the 𝑇! 
based methods, myelin associated water can be identified based on its short 𝑇!∗, 
allowing it to be separated from axonal and interstitial water. In addition, the 
frequency information available with 𝑇!∗ contrast, and not with 𝑇! contrast, improves 
the discrimination between compartments due to their different frequency shifts. 
Furthermore, 𝑇!∗ based techniques can be applied at high field, where they provide 
higher resolution and contrast. Preliminary results obtained with this technique in 
humans suggest that identification of myelin water, and possibly a distinction 
between axonal and interstitial water, is feasible and may have a clinical impact for 
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2 AIMS OF THE STUDIES 
The general aims of this thesis were to study structural and functional brain changes 
in AD and MS, and the underlying biology by using multiple novel MRI techniques, 
alone or combined. The specific aims of each study were:  
 
Paper I 
To study the correlation of pathological changes reflected by CSF biomarkers and 
abnormal functional connectivity extracted from rs-fMRI measurements in AD. 
 
Paper II 
To determine the relationship of CSF biomarkers and brain structural changes 
detected by VBM and DTI in AD. 
 
Paper III 
To investigate preclinical structural brain changes using VBM and DTI in FAD, and 
in relation to CSF biomarkers. 
 
Paper IV 
To evaluate the benefits of 𝑇!∗ based myelin water imaging for the detection of 
demyelination in MS and determine the relationship between demyelination and 
observed changes in myelin, interstitial and axonal water in MS lesions. 
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3 SUBJECTS AND METHODS 
3.1 Ethical approval 
All studies were conducted according to the Declaration of Helsinki and subsequent 
revisions. The studies reported in papers I, II and III were approved by the Regional 
Ethics Committee of Stockholm, Sweden. Paper IV was conducted under an 
institutional review board-approved natural history protocol at the National Institutes 
of Health in Bethesda, USA.  
 
3.2 Subjects 
The participants of papers I and II were recruited from the Memory Clinic at the 
University Hospital of Karolinska Huddinge, in Stockholm, Sweden.  The subjects of 
paper III were from four families with different mutations in APP or PSEN1. The 
clinical routine examinations generally involved physical examination, evaluation of 
neurological and psychiatric status, MMSE testing, and detailed neuropsychological 
assessment, blood and CSF sampling and APOE genotyping. All subjects underwent 
MRI exam on a Siemens whole-body clinical MRI 3T scanner (Magnetom Trio, 
Erlangen, Germany). AD and OD were clinically diagnosis according to the 
Diagnostic and Statistical Manual of Mental Disorders, fourth Edition/International 
Classification of Diseases, 10th revision (DSMIV/ICD-10) criteria. MCI was defined 
using Winblad et al criteria (Winblad et al., 2004). Patients categorized as SCI had 
cognitive memory complaints but without impairment in objective cognitive tasks 
(Reisberg and Gauthier, 2008). 
 
The MS patients of paper IV were recruited from the National Institutes of Health in 
Bethesda, USA. Experienced MS clinicians determined disability according to the 
Expanded Disability Status Scale (EDSS) and obtained clinical data. All MRI were 
performed on a 7T human MRI scanner (Siemens, Erlangen, Germany).  
 
All subjects or their caregivers provided written informed consent to participate in the 
study. 
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3.3 Paper I 
A total of 97 subjects were included in this study (Table 1). All participants 
underwent lumbar puncture to measure the levels of CSF Aβ42, T-tau and P-tau181p. 
All CSF samples were analyzed at Karolinska University Hospital Huddinge. 
The MRI protocol included a high-resolution sagittal 3D 𝑇!-w and rs-fMRI. The main 
acquisition parameters of rs-fMRI included: repetition time (TR)/TE = 1600/35 ms, 
400 time frames of gradient-recalled echo planar imaging, and 42 contiguous oblique 
slices of 4mm thick, and measurements lasted 10min and 30s. During the acquisition 
of rs-fMRI, the subjects were instructed to close their eyes, not to think of anything in 
particular and not to fall asleep. 
 𝑇!-w images were segmented into GM, WM and CSF, and co-registered to the brain 
template from Montreal Neurological Institute using a VBM protocol with FSL 
(FMRIB Software Library, http://www.fmrib. ox.ac.uk/fsl/). After pre-processing, the 
individual DMN map was extracted from rs-fMRI and entered into a voxel-wise 
statistical test to determine the correlation with the ratio of Aβ42/P-tau181p, controlled 
by age, gender and GM intensity map. The correlation between CSF ratio of Aβ42/P-
tau181p and individual average Z-scores of the cluster with statistical significance was 
tested both for AD, MCI, SCI subjects in total and separately adjusted for age and 
gender.   
 
3.4 Paper II 
Twenty-one patients with AD, 35 MCI and 22 SCI from the same cohort as study I 
were studied (Table 2).   
 
DTI was performed using a spin-echo echo planar imaging sequence with the 
Table 1. Demographics.  
 AD (n=21) MCI (n=36) OD (n=17) SCI (n=23) 
Age (y) 65.6±7.1 60.4±9.2 59.3±8.1 57.6±9.1 
Gender (M/F)    8/13 17/19 12/5 9/14 
MMSE 22.3±5.2 26.1±3.2 23.0±4.0 27.7±2.4 
Aβ42 (pg/mL)   483.8±130.8   841.7±352.1   935.4±258.8 1101.0±304.3 
T-tau (pg/mL)   634.7±275.9   356.8±197.8   248.5±103.3   276.7±122.4 
P-tau181p (pg/mL)    88.9±32.9   58.8±24.2   43.8±14.2   51.8±19.4 
Aβ42/P-tau181p    6.6±4.5   18.0±11.0   24.2±10.4 22.9±6.4 
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following acquisition parameters: TR/TE = 5200/91 ms, 42 axial slices (3.6 mm 
thick), in-plane voxel size 2×2 mm2 and 30 orientations for the diffusion-sensitizing 
gradient pulses at a b-value of 1000 s/mm2.  
 
GM intensity map was segmented from 𝑇!-w as in Study I. FA and MD maps were 
generated from DTI on FSL (FMRIB Software Library, http://www.fmrib. 
ox.ac.uk/fsl/) as well. GM intensity, FA and MD maps were entered into a voxel-wise 
statistical analysis to calculate the correlation with CSF Aβ42, T-tau and P-tau181p 
respectively, adjusted for age and gender. For GM intensity maps, we also added 
intracranial volume as a covariate. Then the partial correlations between CSF 
biomarkers and total GM volume, mean FA and MD values of regions with statistical 
significance were tested both for AD, MCI, SCI subjects in total and separately, 
adjusted for age and gender. Similar to the voxel-wise analysis, intracranial volume 
was included as a covariate for GM volume. 
 
3.5 Paper III 
A total of 30 subjects, including 10 MCs and 20 non-carriers (NCs) were included in 
the study. The AAO for each family was 54, 56, 52 and 36 years, respectively. 
Neither the participants nor the investigators were aware of the mutation status of the 
family members during the period of their participation in the study.  One MC was 
diagnosed with AD, and two MCs with MCI.  
 
Eight MCs and 13 NCs underwent a lumbar puncture to measure CSF biomarkers. 
CSF samples were not available for two pre-symptomatic MCs (pre-MCs). All CSF 
samples were simultaneously analyzed for Aβ42, T-tau and P-tau181p at Sahlgrenska 
University Hospital, Mölndal, Sweden, using the methods as described previously in 
detail (Blennow et al., 1995; Vanmechelen et al., 2000; Zetterberg et al., 2008) 
(Table 3). 
Table 2. Demographics. 
 AD (n=21) MCI (n=35) SCI (n=22) 
Age (years) 65.6±7.1 60.3±9.4 56.6±8.1 
Gender (M/F) 8/13 17/18 8/14 
MMSE score 22.3±5.2 26.4±2.8 27.6±2.5 
Aβ42 (pg/mL) 483.8±130.8 826.1±344.3 1089.2±306.0 
P-tau181p (pg/mL) 88.9±32.9 58.8±24.5 51.8±19.8 
T-tau (pg/mL) 634.7±275.9 357.3±200.7 277.1±125.3 
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 𝑇!-w and DTI were acquired from all the subjects. DTI acquisition parameters are as 
follows: TR/TE = 8000/97 ms, 60 axial slices, voxel size = 2×2×2.4 mm3, 30 
orientations for the diffusion-sensitizing gradients with b-value of 1000 s/mm2.  
After the same pre-processing as in study II, GM intensity, FA and MD maps were 
entered into a voxel-wise statistical analysis to compare the difference between pre-
MCs/MCs and NCs, adjusted for age, gender, years of education, APOE ε4 status 
(positive or negative) and ‘years to AAO’. Similar to study II, the partial correlations 
between CSF biomarkers and MD values were tested for the whole sample (adjusted 
for age, gender, years of education and APOE ε4 status).  
 
3.6 Paper IV 
Twenty-five RRMS patients (6 men, 19 women; age range 30-63 years) were 
included. Median EDSS score was 1.5 (range=1–6.5) and mean disease duration was 
8.5 years (range= 0.3–21.6 years). 
 
The mGRE data for mapping the 𝑇!∗ decay curves was acquired with an in-house 
developed pulse sequence by scientists at the National Institutes of Health (van 
Gelderen et al., 2012). Thirty-eight echoes (positive read gradient only) were acquired 
with an echo spacing of 1.6 ms (range from 2.3 to 62.7 ms). TR was 1 s and flip angle 
70°. Fifteen slices with 1.5 mm slice thickness with an in-plane resolution of 1.5 mm 
× 1.5 mm were measured per scan. The slices were parallel to the plane of the 
anterior and posterior commissure line and captured a section of the corpus callosum.  
Table 3. Demographics. 
 pre-MC (n = 7) MC (n = 10) NC (n = 20) 
Age (y) 42.7±8.4 46.5±9.3 48.4±15.1 
Gender, M/F 6/1 8/2 11/9 
Education, years 12.6±2.1 11.9±2.1 11.4±2.3 
MMSE score 29.6±0.5 27.3±5.8 29.2±0.9a 
APOE ε4 carrier, n (%) 4 (57.1) 6 (60.0) 5 (25.0) 
Years to AAO (y) -10.5±9.0 -6.9±9.5 -4.4±12.7 
Aβ42, pg/mL 1094.8±666.5a   901.1±581.8a 1730.1±424.7b 
P-tau181p, pg/mL   45.8±23.3a   60.6±30.4a 43.2±14.0b 
T-tau, pg/mL   326.6±183.7a   504.1±364.2a 297.2±126.0b 
a Data missing for two subjects 
b Data missing for seven subjects. 
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All mGRE imaging analyses were similar to our previous study (Sati et al., 2013). 
The average complex signal of interested regions was calculated and fitted to a three-
component model using the following equation.  𝑆 = (𝐴!𝑒 !!/!!,!∗ !!!!∆!! ! + 𝐴!𝑒 !!/!!,!∗ !!!!∆!! ! + 𝐴!𝑒(!!/!!,!∗ )!)𝑒! !!!!!!!  
Here, 𝐴!   is the amplitude, 𝑇!,!∗  the relaxation time, ∆𝑓!   the frequency shift of 
component n, which is defined relative to global / interstitial water frequency fg, 𝜑 is 
the phase offset. Components 1, 2 and 3 were assigned to myelin, axonal and 
interstitial water respectively (van Gelderen et al., 2012; Sati et al., 2013). Based on 
our preliminary data, the starting values for the fitting were defined as 𝐴! = 0.16, 𝐴! = 0.43 , 𝐴! = 0.41 ; 𝑇!,!  ∗ = 6.3  𝑚𝑠 ,   𝑇!,!  ∗ =   41.7  𝑚𝑠 , 𝑇!,!∗ = 26.3  𝑚𝑠 ; ∆𝑓! =21  𝐻𝑧, ∆𝑓! = −6  𝐻𝑧, 𝑓! = 0  𝐻𝑧, 𝜑 = 0  𝐻𝑧. For the analyses of lesions, the 𝑇!,!∗   and ∆𝑓! were fixed at values from contralateral NAWM as the myelin water signal in 
lesions proved to be too small to determine these independently. A range of values 
was tested, which did not change the results significantly.  
 
A t-test was used to compare differences between enhancing lesions and NAWM, 
non-enhancing lesions and NAWM, and enhancing versus non-enhancing lesions for 
the three-component fitting results.  
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4 RESULTS AND DISCUSSIONS 
4.1 Association between functional and structural brain changes 
and CSF biomarkers in sporadic AD 
The time course and spatial distribution of amyloid and tau deposition suggest that 
the progression of AD shows some regional specificity (Braak and Braak, 1997). 
Some regions of the DMN showed high levels of amyloid deposition in these 
patients. Furthermore, the functional connectivity between brain regions of the DMN 
is disrupted in elderly normal adults with amyloid deposition (Hedden et al., 2009; 
Sheline et al., 2010). rs-fMRI is thought to be a synaptic biomarker. There is evidence 
that soluble oligomers of Aβ can selectively impair synaptic plasticity to disrupt 
synaptic function both in mice model and in vitro (Arendt, 2009). These suggest that 
this neural activity within DMN may provide information of regional changes caused 
by amyloid deposition.  
 
Low CSF Aβ42 and high T-tau and P-tau181p levels were associated with AD 
pathology, amyloid plaques and hyperphosphorylated tau, respectively (Seppälä et al., 
2012). CSF ratio of Aβ42/P-tau181p showed superior diagnostic usefulness than either 
measure alone (Maddalena et al., 2003; Ibach et al., 2006). In study I, the correlation 
of brain functional connectivity within DMN and CSF ratio Aβ42/P-tau181p was 
investigated.  We found a positive correlation between the ratio of Aβ42/P-tau181p and 
functional connectivity within the DMN in left precuneus/cuneus (Figure 4). 
Anatomical and connectivity data seem to suggest a relevant role for the precuneus in 
 
Figure 4. The correlation between functional connectivity within DMN and CSF ratio of 
Aβ42/P-tau181p in AD. One cluster within DMN shows positive correlation with the ratio 
of Aβ42/P-tau181p, adjusted for age, gender and GM intensity map. The cluster consists 
of 17 voxels, peak T score is 3.44 and located in left precuneus. However, the most part 
of the cluster is in the left cuneus.  
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the implementation of a wide range of cognitive functions, including episodic 
memory retrieval, visuospatial imagery, self-processing and others (Cavanna and 
Trimble, 2006). Evidence indicated that precuneuc/cuneus participate during the 
switching of attention (Le et al., 1998). In addition, the precuneus/cuneus have been 
reported to be associated with brain changes in AD and MCI patients, such as Aβ42 
deposition, cerebral blood flow and glucose metabolism changes (Buckner et al., 
2005; Bai et al., 2008; Petrie et al., 2009; Tosun et al., 2011; Luo et al., 2012). Our 
results are consistent with previous reports. Moreover, the findings support the view 
that impaired synaptic function, which is evaluated by rs-fMRI is related to amyloid 
deposition, pathological tau process and progresses with disease severity.  
 
Buckner et al. (Buckner et al., 2005) noted that neuropathology, atrophy, and 
metabolism all display similar profiles on the cortical surface in patients with AD. 
After the association between functional changes and CSF biomarkers was observed 
in study I, the relationships of CSF biomarkers and structural brain changes were 
investigated in study II. The accumulation of intraneuronal NFTs and extracellular 
APs are the neuropathologic characteristic of the AD brain, which could lead to 
neuronal death and disturbances of tissue homogeneity (Chua et al., 2008), and 
increase water diffusion of brain tissue (Fellgiebel et al., 2004). These structural brain 
alterations could be indicated by GM volume, FA and MD changes. We found that 
GM volume and MD changes correlated with CSF Aβ42 and T-tau, FA associated 
with CSF Aβ42 (Figure 5). No significant correlations between P-tau181p and GM 
volume, FA and MD changes were found; this may be due to the presence of other 
tau proteins, such as phosphorylated tau at position threonine 231 and serine 199, 
which have been reported with similar diagnostic performances for AD (Hampel et 
al., 2004).  
 
It is interesting that the majority of regions with significant correlations between 
structural brain changes and CSF biomarkers overlapped the DMN and extended to 
the adjacent WM. It has been demonstrated that the DMN reflects the underlying 
structural connectivity architecture of the human brain, including the cingulum tract, 
superior frontal-occipital fasciculus and the genu of the corpus callosum (van den 
Heuvel et al., 2009; Greicius et al., 2009; Teipel et al., 2010). The regions with 
significant correlations overlapped the limbic system as well. The limbic system is a 
group of interconnected cortical and subcortical structures dedicated to linking 
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emotion to cognition and behavior (Yu et al., 2014). The limbic system plays a key 
role in AD, which is related to the accumulation of APs and NFTs (Braak and Braak, 
1991). Although the exact cause of these changes has not been identified, all our 
results support the view that AD brain pathological changes, which are reflected by 
CSF biomarkers, could be detected with rs-fMRI, VBM analysis and DTI 
measurements.   
 
 
Figure 5. Brain regions with significant correlations between CSF biomarkers and GM 
volume, FA and MD. The images are overlaid on the MNI template. The green color 
shows the DMN template. The red and blue colors denote the regions with significant 
correlations (with cluster-forming threshold t > 2.66).  
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To test whether different MRI modalities could be used effectively to detect AD 
pathological changes at different disease stages; the relationship between CSF 
biomarkers and functional connectivity, GM volume, FA and MD changes for each 
individual diagnostic group was evaluated separately (Table 4). In the AD group, 
only correlation between FA and CSF Aβ42 was observed. In addition, FA was 
associated with CSF Aβ42 only in occipital cortex and underlying white matter for 
the entire cohort, which is likely involved in amyloid deposition at the late stage of 
AD (Braak and Braak, 1991). For the patients with MCI, both rs-fMRI and DTI 
measurements were associated with CSF biomarkers. While for the subjects with SCI, 
only MD significantly correlated CSF Aβ42 and T-tau. Taken together, our results 
support Sperling’s hypothetical model of dynamic biomarkers of AD (Sperling et al., 
2011), which was adapted from a theory proposed by Jack et al (Jack et al., 2010). 
None of the biomarkers is static; rates of change in each biomarker change over time 
and represent a sigmoid shaped trajectory. At a given point in time, rate of change of 
biomarkers might be different although they have the same shape over the course of 
disease progression. For the entire cohort, the CSF biomarkers were associated with 
functional and structural brain changes, whereas the relationship changed at different 
disease stages. In addition, the biomarker of Aβ deposition, which becomes abnormal 
early in this model, was associated with MD changes. This suggests that 
microstructural alterations in the brain indexed by MD are an early event in AD 
pathogenesis, which could be used to detect pathological changes at an early stage.  
Table 4. Partial correlations between CSF biomarkers and rs-fMRI measurement, GM 
volume, mean FA and MD of the brain regions with statistical significance. 
 Total a AD MCI SCI 
 r p r p r p r p 
rs-fMRI         
Aβ42/P-tau181p b 0.33 < 0.01  0.03 0.90  0.50 < 0.01 -0.08   0.72 
GM         
Aβ42 c 0.35 < 0.01 -0.08 0.75  0.29    0.11 -0.09   0.72 
T-tau c -0.30 < 0.01  0.21 0.41 -0.15    0.41 -0.06   0.82 
FA         
Aβ42 b 0.52 < 0.01  0.50 0.03  0.41   0.02  0.40   0.08 
MD         
Aβ42 b -0.62 < 0.01 -0.39 0.10 -0.60 < 0.01 -0.68 < 0.01 
T-tau b  0.65 < 0.01  0.36 0.14  0.61 < 0.01  0.67 < 0.01 
a Total refers to all subjects with AD, MCI and SCI. 
b Adjusted for age, gender. 
c Adjusted for age and gender and intracranial volume.  
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4.2 Correlation of preclinical structural brain changes and CSF 
biomarkers in familial AD 
The pathophysiological process of AD is thought to begin many years before the 
diagnosis of AD dementia (Sperling et al., 2011).  The increasing age of the 
population is leading to an increased prevalence of AD in the world. It is critical to 
identify individuals developing AD at a very early stage and estimate the timing of 
dementia onset. Studies on familial AD MCs can be particularly valuable for 
investigating disease progression at early stages due to the high likelihood of 
developing AD. For this purpose, a small cohort of FAD MCs was studied in study 
III. We found that MCs showed lower CSF Aβ42 and higher P-tau181p and T-tau 
levels in the CSF, even though most of them are pre-MCs, which is consistent with 
previous reports. It also supports the view that AD pathological changes begin many 
years before onset of clinical symptom.  
  
In our sporadic AD study, correlations between MD changes and CSF Aβ42 and T-
tau were observed in SCI group. To further confirm these findings, we compared the 
 
Figure 6. Increased MD in pre-MCs and MCs compared with NCs. (a) MD was 
significantly increased in the left inferior longitudinal fasciculus and cingulum and 
bilateral superior longitudinal fasciculus in pre-MCs compared with NCs (red-yellow). 
(b) When three symptomatic MCs are included in the analysis, the area with significant 
differences widens (red-yellow).  
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GM volume, FA and MD between FAD pre-MCs/MCs and NCs in study III. A 
significantly increased MD in pre-MC compared with NC in the left inferior 
longitudinal fasciculus and cingulum and bilaterally in the superior longitudinal 
fasciculus was found (Figure 6a). When including the three symptomatic MCs, the 
regions became wider (Figure 6b). There were no significant differences in whole-
brain GM volume and FA between pre-MCs and NCs or between MCs and NCs. 
Interestingly, the regions with statistical significance also overlapped the limbic area. 
Using the same non-image partial correlation analyses as study I and II, not 
surprisingly, the mean MD values from these regions showed a statistically 
significant negative correlation with CSF Aβ42, and positive correlation with P-
tau181p and T-tau for all subjects (Figure 7). These are all consistent with our previous 
results that MD may reflect pathology at very early stage and could be a potential 
biomarker of preclinical AD.  
 
4.3 Quantitative analyses of white matter changes in MS lesions 
In study IV, a novel MRI technique, involving the fitting of a three-component model 
to the 𝑇!∗  relaxation behavior, was used to detect and characterize ongoing 
demyelination in MS lesions.  
 
This method provides a measure of the amount of water trapped between the myelin 
layers, which is generally considered to reflect brain myelin content. The myelin 
bilayer is made up of lipid and protein. Water fills between the bilayers, which makes 
up approximately 40% of the weight of myelin (Laule et al., 2007). A decreased 
amount of myelin water was found in both enhancing and non-enhancing lesions 
 
Figure 7. Partial correlations between AD CSF biomarkers and MD. Scatter plots show 
the partial correlations between CSF Aβ42 (a), P-tau181p (b) and T-tau (c) and MD from 
regions with a statistically significant difference between the MC and NC groups, 
adjusted for age, gender, years of education and APOE ε4 status. There was a significant 
negative correlation between the MD value and CSF Aβ42; positive correlations were 
seen between the MD value and CSF levels of both P-tau181p and T-tau. 
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compared to the contralateral NAWM, which suggests ongoing demyelination in 
these lesions (Figure 8a). Increased interstitial and axonal water indicates water 
moving from between myelin layers to the extracellular and/or axonal compartments 
during the demyelination process.  
 
We also found longer relaxation time 𝑇!∗ of interstitial and axonal water in lesions 
when compared to the contralateral NAWM (Figure 8b), which has been reported to 
correspond to the myelin loss in MS lesions (Yao et al., 2012; Lee et al., 2012). In 
previous 𝑇!-based myelin water studies, the 𝑇! of myelin water (10ms < 𝑇! < 50ms) 
was not well defined, which could lead to a possible overestimation of the myelin 
water fraction (Du et al., 2007). Moreover, the intra- and extra-cellular water (𝑇! ≈ 
80-100ms) was computing as one component (MacKay et al., 1994; Laule et al., 
2004; Björk et al., 2015). This compartment-specific 𝑇!∗ relaxation used in the study 
arises from differences in water mobility in the different pools, which improved the 
 
Figure 8. Significance of the differences in three-component fitting results between 
enhancing and non-enhancing lesions, and NAWM.  In both enhancing and non-
enhancing lesions, the amplitude of myelin water was significantly decreased, and 
interstitial and axonal water was increased compare to the contralateral NAWM (a). 
While comparing with NAWM, lesions also showed longer 𝑇!∗ for interstitial and 
axonal water (b), and lower frequency shift for axonal water (c). 
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accuracy in separation of the three components.  
 
In addition, a smaller frequency shift for axonal water in lesions was observed 
relative to NAWM (Figure 8c). In WM, compartment-specific resonance frequency 
shifts may occur due to the magnetic susceptibility effects of the distribution of 
myelin-associated lipids and iron. MRI susceptibility effects in WM have strong 
contributions from tissue nanostructure and microstructure (Sati et al., 2013). It has 
been reported that altered frequency contrast indicated myelin damage, which is 
consistent with our results (Yablonskiy et al., 2012).  
 
These findings suggest that the fitting of a three-component model to the 𝑇!∗ decay 
curve in MS lesions may help to quantify myelin loss. Moreover, in MS lesions, 
increased 𝑇!∗  and lower frequency shift for axonal water could help us further 
understand the microstructural changes, which may relate to axonal loss and 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
In this thesis, we studied functional and structural brain changes in two 
neurodegenerative diseases, AD and MS, with novel MRI techniques, including rs-
fMRI, VBM analysis, DTI and separation of 𝑇!∗ relaxation components.  
 
AD is the most common neurodegenerative disease. The disease is currently 
diagnosed when affected patients meet criteria for dementia, a stage at which the 
brain has suffered sufficient damage to severely impact cognition. There is increasing 
recognition that such a late diagnosis poses major challenges for managing the 
disease and finding effective therapies. Recognizing AD when persons experience 
only very mild cognitive deficits or subjective cognitive symptoms would support the 
development of disease-modifying therapies, the identification of a more appropriate 
therapeutic window, and the determination of individuals who would benefit most 
from early interventions. In this thesis, rs-fMRI, VBM analysis, DTI were used to 
investigate brain pathological evolution of AD in a continuum cohort, including AD, 
MCI, SCI and FAD pre-MCs. We found that functional and structural brain changes 
detected by MRI, both in sporadic and familial AD, were associated with CSF 
biomarkers, which are thought to reflect pathological changes in the brain. And these 
regions with significant changes are relevant to the DMN. We believe that these 
results will contribute to the understanding of the progression of AD pathology and 
aid in the diagnosis of AD at an early stage. Moreover, MD is a potential biomarker 
of preclinical AD.  
 
MS is another common neurodegenerative disease. The clinical courses of MS are 
heterogeneous with infinite variety of symptoms and unpredictable recurrent attacks 
(Lucchinetti et al., 2001). The mechanisms of ongoing deterioration observed in 
progressive MS are still unclear. MS subtypes can be categorized as relapsing or 
progressive based on the natural history of the disease, but these categories do not 
provide temporal information about the ongoing disease process. Evidence of disease 
activity and clinical progression may impact prognosis and therapeutic decisions. 
Various in vivo MRI techniques have been used to study the pathological evolution of 
MS. Here, we used a new MRI technique, involving separation of 𝑇!∗ relaxation 
components, to study the demyelination in a clinical MS cohort at 7T. This further 
validates the feasibility of this new technique to detect demyelination in MS patients 
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and myelin water fraction as a marker for myelin. It also supports the use of myelin 
water imaging to study myelin pathology. Moreover, compared to 𝑇!-based myelin 
water imaging, it improved the accuracy in separation of myelin water, axonal water 
and interstitial water components due to the compartment-specific 𝑇!∗ relaxation and 
frequency shifts. Furthermore, increased 𝑇!∗ and lower frequency shift for axonal 
water may reflect microstructural changes, probably the axonal damage in MS lesion, 
and help to further characterize tissue damage in this disease. Additional longitudinal 
work is warranted, which can lead to a better understanding of, and prognostic ability 
for, this complex disease.  
 
The experimental findings reported here are consistent with expectations based on 
prior radiological and pathological work, and are helpful in further understanding 
pathological evolution in AD and MS. In addition, more and more evidence shows 
AD, MS and some other neurodegenerative diseases have common features, including 
pathology. With these novel MRI techniques it is possible to screen individuals 
susceptible to and/or manifesting functional and structural brain changes with disease 
pathological evolution. For instance, white matter alterations in confirmed AD are a 
combination of axonal and myelin alteration (Englund et al., 1988; Bendlin et al., 
2012). Histological studies have demonstrated a widespread decrease in myelin that 
has been observed in normal-appearing white matter, as well as more severe myelin 
loss in focal regions in AD (Fernando et al., 2004). Biochemical analyses of AD 
white matter revealed increased quantities of Aβ40 and Aβ42 accompanied by 
significant decreases in the amounts of myelin protein (Bartzokis, 2004). On the other 
hand, the finding of APP expression in axons around the plaque in MS, as well as the 
correlation of Aβ with different stages of MS has clearly indicated that amyloid plays 
some kind of key role in MS disease pathogenesis (Chandra, 2015). Axonal loss 
occurs in all demyelinated MS lesions and is considered the main cause of 
irreversible chronic disease progression in MS (Bitsch et al., 2000). There is 
increasing evidence that damage to WM can occur either to the myelin or to the axon 
with subsequent damage to the other (Tsunoda and Fujinami, 2002). The application 
of the separation of 𝑇!∗ relaxation components in AD may help to further understand 
WM changes in this disease and the underlying mechanisms. Comparison of the 
relationship between brain changes and amyloid deposition in different 
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neurodegenerative diseases could be beneficial in understanding disease progression, 
and in enabling preventive and more effective treatment of the patients.  
 
To conclude, the results presented in this thesis show the potential of novel MRI 
techniques in detecting pathological evolution of neurodegenerative diseases. These 
non-invasive techniques may someday be used in clinical practice to help diagnosis 
and monitor neurodegenerative disease progression. Furthermore, these methods 
could be used in clinical trials to assist in the development of new drugs.  
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